JAMA Oncology

Papers
(The H4-Index of JAMA Oncology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?1424
JAMA Oncology565
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?512
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data390
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer347
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply318
Information Blocking and Oncology294
Error in Text283
Errors in Key Points and Abstract266
Stargazers264
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen245
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply242
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants236
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer234
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer233
Overall Survival in the CAIRO5 Clinical Trial229
Piercing the Fog209
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults185
Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer185
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!183
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia179
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses171
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ERBB2-Negative Early Breast Cancer167
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer163
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors147
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab142
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab135
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors135
Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer131
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers128
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply127
The Multidisciplinary Cancer Conference126
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?125
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention124
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer123
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology123
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades118
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration117
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply116
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US114
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?111
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply108
Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply107
Is Colorectal Cancer Screening Absolutely Beneficial for Older Adults?103
The SOUND Randomized Clinical Trial Results102
Results of the TARGET-TP Randomized Clinical Trial101
Variability in COVID-19 Vaccine Response Among People With Cancer99
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?99
An Atypical Rash on the Chest98
Immunotherapy Before Chemoradiotherapy—More Is Better?97
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply96
Shifting Toward Precision Oncology in SCLC Treatment94
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories94
Trauma92
JAMA Oncology90
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer87
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable86
Error in Text85
Coding Errors in Study of Eligibility for Lung Cancer Screening85
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence83
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer82
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply82
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set81
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy81
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis80
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy78
JAMA Oncology78
Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China78
Clinical Trial Diversity—Will We Know It When We See It?77
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis77
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation77
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy76
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 201975
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients74
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia74
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”74
0.14749598503113